Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 16/20 | 0.59 |
| ▸ | EZH1 | Q92800 | 10/20 | 0.59 |
| ▸ | EED | O75530 | 3/20 | 0.53 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.53 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.51 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.51 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.51 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.51 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12180264 | 0.90 | EZH2 (0.64) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL2595015 | 0.89 | EZH2 (0.65) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL14717208 | 0.87 | EZH2 (0.58) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL14718181 | 0.87 | EZH2 (0.61) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL12180108 | 0.86 | EZH2 (0.61) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL17956118 | 0.86 | EZH2 (0.61) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL2592121 | 0.86 | EZH2 (0.62) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL12180406 | 0.86 | EZH2 (0.61) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL2592752 | 0.86 | EZH2 (0.59) | EZH2EZH1EEDSUZ12PRMT3 | |
| SCHEMBL12180100 | 0.86 | EZH2 (0.53) | EZH2EZH1EEDSUZ12RBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | claimed |